Bellina Mélanie, Bernet Agnès
Centre de recherche en cancérologie de Lyon (CRCL), Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France.
Med Sci (Paris). 2022 Apr;38(4):351-358. doi: 10.1051/medsci/2022038. Epub 2022 Apr 29.
Netrin-1, a secreted molecule that was first described for its role in guidance during embryogenesis, was then brought to light for its overexpression in a large number of aggressive cancers. Netrin-1 is a ligand of "dependence receptors". In adults, the interaction between Netrine-1 and these receptors triggers the survival, proliferation, and migration of different cell types. This will confer better survival properties to tumor cells, making them more prone to form aggressive tumors. A recently developed novel therapy aims at inhibiting the binding of Netrin-1 to these receptors in order to trigger cell death by apoptosis. This article presents a review of the functional characteristics of the Netrin-1 molecule, and the potential effects of a novel targeted therapy against Netrin-1 that could lead to very promising results in combination with conventional anti-cancer treatments.
Netrin-1是一种分泌分子,最初因其在胚胎发育过程中的导向作用而被描述,随后又因其在大量侵袭性癌症中的过表达而受到关注。Netrin-1是“依赖受体”的配体。在成体中,Netrin-1与这些受体之间的相互作用会触发不同细胞类型的存活、增殖和迁移。这将赋予肿瘤细胞更好的存活特性,使其更容易形成侵袭性肿瘤。最近开发的一种新型疗法旨在抑制Netrin-1与这些受体的结合,从而通过凋亡触发细胞死亡。本文综述了Netrin-1分子的功能特性,以及针对Netrin-1的新型靶向疗法的潜在效果,这种疗法与传统抗癌治疗联合应用可能会产生非常有前景的结果。